AEZS Stock Overview
A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aeterna Zentaris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$11.50 |
| 52 Week High | CA$16.92 |
| 52 Week Low | CA$7.64 |
| Beta | 2.08 |
| 1 Month Change | 6.58% |
| 3 Month Change | 14.09% |
| 1 Year Change | -25.52% |
| 3 Year Change | -89.55% |
| 5 Year Change | -95.79% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely
May 10
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow
Nov 12Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
Jul 15Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth
Mar 29Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years
Feb 04Shareholder Returns
| AEZS | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -1.1% | 10.1% | -0.5% |
| 1Y | -25.5% | -25.6% | 11.9% |
Return vs Industry: AEZS matched the Canadian Biotechs industry which returned -25.6% over the past year.
Return vs Market: AEZS underperformed the Canadian Market which returned 11.9% over the past year.
Price Volatility
| AEZS volatility | |
|---|---|
| AEZS Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: AEZS has not had significant price volatility in the past 3 months.
Volatility Over Time: AEZS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Klaus Paulini | www.zentaris.com |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
Aeterna Zentaris Inc. Fundamentals Summary
| AEZS fundamental statistics | |
|---|---|
| Market cap | CA$15.78m |
| Earnings (TTM) | -CA$24.61m |
| Revenue (TTM) | CA$3.24m |
4.3x
P/S Ratio-0.6x
P/E RatioIs AEZS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEZS income statement (TTM) | |
|---|---|
| Revenue | US$2.37m |
| Cost of Revenue | US$221.00k |
| Gross Profit | US$2.15m |
| Other Expenses | US$20.20m |
| Earnings | -US$18.05m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.87 |
| Gross Margin | 90.69% |
| Net Profit Margin | -760.28% |
| Debt/Equity Ratio | 0% |
How did AEZS perform over the long term?
See historical performance and comparison